189 related articles for article (PubMed ID: 16467090)
21. Identification of pathways associated with invasive behavior by ovarian cancer cells using multidimensional protein identification technology (MudPIT).
Sodek KL; Evangelou AI; Ignatchenko A; Agochiya M; Brown TJ; Ringuette MJ; Jurisica I; Kislinger T
Mol Biosyst; 2008 Jul; 4(7):762-73. PubMed ID: 18563251
[TBL] [Abstract][Full Text] [Related]
22. Tumor microenvironment: what can effusions teach us?
Kassis J; Klominek J; Kohn EC
Diagn Cytopathol; 2005 Nov; 33(5):316-9. PubMed ID: 16240401
[TBL] [Abstract][Full Text] [Related]
23. Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma.
Bunkholt Elstrand M; Dong HP; Ødegaard E; Holth A; Elloul S; Reich R; Tropé CG; Davidson B
Hum Pathol; 2010 Jun; 41(6):794-804. PubMed ID: 20153512
[TBL] [Abstract][Full Text] [Related]
24. Malignant effusions: from diagnosis to biology.
Davidson B
Diagn Cytopathol; 2004 Oct; 31(4):246-54. PubMed ID: 15452897
[TBL] [Abstract][Full Text] [Related]
25. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
26. Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities.
Reich R; Vintman L; Nielsen S; Kaern J; Bedrossian C; Berner A; Davidson B
Diagn Cytopathol; 2005 Nov; 33(5):332-7. PubMed ID: 16240397
[TBL] [Abstract][Full Text] [Related]
27. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.
Mezzanzanica D; Fabbi M; Bagnoli M; Staurengo S; Losa M; Balladore E; Alberti P; Lusa L; Ditto A; Ferrini S; Pierotti MA; Barbareschi M; Pilotti S; Canevari S
Clin Cancer Res; 2008 Mar; 14(6):1726-33. PubMed ID: 18347173
[TBL] [Abstract][Full Text] [Related]
28. D2-40 is not a specific marker for cells of mesothelial origin in serous effusions.
Bassarova AV; Nesland JM; Davidson B
Am J Surg Pathol; 2006 Jul; 30(7):878-82. PubMed ID: 16819331
[TBL] [Abstract][Full Text] [Related]
29. Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion.
Benlloch S; Galbis-Caravajal JM; Martín C; Sanchez-Paya J; Rodríguez-Paniagua JM; Romero S; Mafe JJ; Massutí B
Cancer; 2006 Oct; 107(8):1859-65. PubMed ID: 16983705
[TBL] [Abstract][Full Text] [Related]
30. The diagnostic role of claudins in serous effusions.
Kleinberg L; Holth A; Fridman E; Schwartz I; Shih IeM; Davidson B
Am J Clin Pathol; 2007 Jun; 127(6):928-37. PubMed ID: 17509990
[TBL] [Abstract][Full Text] [Related]
31. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
Afify A; Lynne LC; Howell L
Diagn Cytopathol; 2007 Feb; 35(2):105-10. PubMed ID: 17230576
[TBL] [Abstract][Full Text] [Related]
32. Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion.
Davidson B; Smith Y; Nesland JM; Kærn J; Reich R; Tropè CG
Hum Pathol; 2013 Nov; 44(11):2449-60. PubMed ID: 24011953
[TBL] [Abstract][Full Text] [Related]
33. Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma.
Kleinberg L; Flørenes VA; Silins I; Haug K; Trope CG; Nesland JM; Davidson B
Cancer; 2007 Jan; 109(2):228-38. PubMed ID: 17167759
[TBL] [Abstract][Full Text] [Related]
34. The effect of malignant effusions on methotrexate disposition.
Li J; Gwilt P
Cancer Chemother Pharmacol; 2002 Nov; 50(5):373-82. PubMed ID: 12439595
[TBL] [Abstract][Full Text] [Related]
35. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J
Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282
[TBL] [Abstract][Full Text] [Related]
36. [Clinical significance of CEA mRNA detection in pleural and peritoneal effusions by real-time fluorescent quantitative RT-PCR].
Zhang X; Cao J; Zheng S; Li XF
Zhonghua Wai Ke Za Zhi; 2003 Jun; 41(6):411-3. PubMed ID: 12895345
[TBL] [Abstract][Full Text] [Related]
37. Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping.
Sigstad E; Dong HP; Nielsen S; Berner A; Davidson B; Risberg B
Diagn Cytopathol; 2005 Nov; 33(5):325-31. PubMed ID: 16240402
[TBL] [Abstract][Full Text] [Related]
38. NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma.
Dong HP; Elstrand MB; Holth A; Silins I; Berner A; Trope CG; Davidson B; Risberg B
Am J Clin Pathol; 2006 Mar; 125(3):451-8. PubMed ID: 16613351
[TBL] [Abstract][Full Text] [Related]
39. Serous effusions in malignant lymphomas: a review.
Das DK
Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559
[TBL] [Abstract][Full Text] [Related]
40. Survival of patients with malignancy-associated effusions.
van de Molengraft FJ; Vooijs GP
Acta Cytol; 1989; 33(6):911-6. PubMed ID: 2588923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
